MA-DESKTOP-METAL
19.4.2022 14:32:12 CEST | Business Wire | Press release
Desktop Metal (NYSE: DM) today announced the launch of the ExOne S-Max® Flex, a scalable, large-format binder jetting system that 3D prints sand tooling, which foundries use to quickly cast complex metal designs for the aerospace, automotive, and energy industries, among others.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220419005064/en/
ExOne, which was acquired by Desktop Metal in late 2021, is the leading digital sand printing solution provider for foundries. The new S-Max Flex combines ExOne’s sand printing expertise in process and materials with proprietary Desktop Metal SPJ technology in an affordable architecture to deliver new value to foundries that have long wanted an S-Max but found the premium price out of reach.
The S-Max Flex will debut at CastExpo 2022, North America’s largest metalcasting trade show, from April 23-26 in Columbus, Ohio. A video highlighting the benefits of the S-Max Flex for early customers, including Alpha Foundry of Wright City, Mo., and D.W. Clark in Taunton, Mass., was released today at www.exone.com/flexvideo .
“To achieve our vision of Additive Manufacturing 2.0, we need to make production 3D printing practical in terms of speed, cost, and material availability for a broad range of applications,” said Ric Fulop, Co-Founder and CEO of Desktop Metal. “We designed the all-new S-Max Flex from the ground up leveraging SPJ technology with the idea of making premium sand 3D printing accessible to every foundry, so that more companies can take advantage of the benefits of AM 2.0, such as distributed, local production, and remain competitive for the long term.”
The S-Max Flex comes to market at a time of strong demand for castings, along with challenges finding labor. After years of contraction, the U.S. metalcasting industry is experiencing growth as a result of supply chain changes related to the COVID-19 pandemic. A recent survey released by the American Foundry Society shows that 90 percent of responding North American foundries have a positive business outlook and anticipate making capital investments in the next 12 months, including of 3D printers.
Additional early buyers of the new S-Max Flex include Founders Service & Manufacturing Co. Inc. of Deerfield, Ohio, and HTCI Co. of New Carlisle, Ohio.
Details of the S-Max Flex
The S-Max Flex pairs an affordable industrial robot with an all-new end effector printhead design that deposits binder into a 1900 x 1000 x 1000 mm (74 x 39 x 39 in) telescoping build box that grows as the parts are built layer by layer. Additional build box sizes are available up to 4700 x 1000 x 1000 mm (185 x 39 x 39 in), with taller versions available up to 1000 x 2500 x 2400 mm (39 x 98 x 94 in).
Desktop Metal’s high throughput SPJ technology delivers a build rate up to 115 l/h, which offers foundries quick and reliable production to operate more efficiently in times of ongoing labor shortages, as well as a faster return on investment. The S-Max Flex joins the premium S-Max® and S-Max® Pro solutions that are used in foundries worldwide.
The all-new S-Max Flex prints standard silica sand with furan binders and delivers final parts with dimensional accuracy of +/- 0.5 mm. The system comes with several accessories and safety features that are configurable to fit a variety of spaces.
Industries beyond metalcasting are also set to take advantage of the S-Max Flex’s large form factor and ability to binder jet a variety of powders. Infiltrated sand tooling for plastic thermoforming, composite layup, and sacrificial tooling applications are printed today on S-Max machines, along with infiltrated sand consumer products, such as those offered by Sandhelden and Deeptime . Desktop Metal’s Forust brand, which upcycles byproducts of the wood waste stream into consumer designs, will also leverage the new system to print large form factor wood parts at scale cost-effectively. Additional projects are underway printing reclaimed concrete and other materials.
Binder Jetting - the Fastest AM Method for Mass Production
Binder jet 3D printing is widely regarded as the fastest additive manufacturing method for the mass production of functional precision parts. Sand binder jet 3D printing has been used in foundries for more than two decades to create metalcasting tooling cost-effectively and with low turnaround times.
In the binder jetting process, an industrial printhead selectively deposits a binder into a bed of sand particles creating a solid part one thin layer at a time, similar to printing on sheets of paper. 3D printing straight from CAD files enables foundries to eliminate the months-long lead times and high costs of traditional patterns and coreboxes created from wood or metal. The design freedom of additive manufacturing also allows designers to innovate the parts made with the reliable casting process – creating complex, consolidated geometries that enable lightweighting and optimized part performance not possible with traditional processes.
For more information on the ExOne S-Max Flex system, visit www.exone.com .
About Desktop Metal
Desktop Metal, Inc., based in Burlington, Massachusetts, is accelerating the transformation of manufacturing with an expansive portfolio of 3D printing solutions, from rapid prototyping to mass production. Founded in 2015 by leaders in advanced manufacturing, metallurgy, and robotics, the company is addressing the unmet challenges of speed, cost, and quality to make additive manufacturing an essential tool for engineers and manufacturers around the world. Desktop Metal was selected as one of the world’s 30 most promising Technology Pioneers by the World Economic Forum, named to MIT Technology Review’s list of 50 Smartest Companies, and the 2021 winner of Fast Company’s Innovation by Design Award in materials and Fast Company’s Next Big Things in Tech Award for sustainability. For more information, visit www.desktopmetal.com
.
Forward-looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. Forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks, uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to, the risks and uncertainties set forth in Desktop Metal, Inc.'s filings with the U.S. Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Desktop Metal, Inc. assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220419005064/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
